Evidence map›Paper›PMID 42450196›Full record

ArticleInternational journal of molecular sciences2026

Prenylated p-Coumaric Acid Derivatives Mitigate Neurobehavioral and Neuroinflammatory Alterations Associated with Experimental Colitis.

Camila A Cazarin, Bruna Longo, Eduarda R Bauer, Morgana S Machado, Maria I Basílio, Tauani C S França, Thiago F de Q E Silva, Benhur J Cury, Larissa Venzon, Ana C Dos Santos and 9 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Camila A CazarinPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.ORCID 0000-0003-3528-646X
Bruna LongoLaboratory of Pharmacology Applied to the Gastrointestinal Tract and its Interactions, Department of Pharmacology, Federal University of Santa Catarina, Florianópolis 88037000, SC, Brazil.ORCID 0000-0002-2766-5390
Eduarda R BauerPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
Morgana S MachadoPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
Maria I BasílioPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
Tauani C S FrançaPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
Thiago F de Q E SilvaPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
Benhur J CuryLaboratory of Pharmacology Applied to the Gastrointestinal Tract and its Interactions, Department of Pharmacology, Federal University of Santa Catarina, Florianópolis 88037000, SC, Brazil.ORCID 0009-0007-1408-3328
Larissa VenzonPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
Ana C Dos SantosPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
Heloísa I EisendeckerPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
Luiza F CorsiPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
Alex W ValachinskiPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
Sérgio F de AndradeResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.ORCID 0000-0001-9294-7290
Victor P RibeiroSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040903, SP, Brazil.ORCID 0000-0002-5015-2446
Matheus H TanimotoSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040903, SP, Brazil.ORCID 0000-0002-1063-3026
Jairo K BastosSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040903, SP, Brazil.ORCID 0000-0001-8641-9686
Luísa M da SilvaLaboratory of Pharmacology Applied to the Gastrointestinal Tract and its Interactions, Department of Pharmacology, Federal University of Santa Catarina, Florianópolis 88037000, SC, Brazil.
Márcia M de SouzaPharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001
6 · The paper itself

Abstract

Inflammatory bowel disease is an inflammatory disorder associated with systemic immune activation, contributing to neuroinflammation, behavioral impairments and disruption of the gut-brain axis. The present study investigated the effects of p-Coumaric acid derivatives: Artepillin C (ART-C), Baccharin (BAC), and Drupanin (DRU) on colonic damage, behavioral alterations, and oxidative stress in a dextran sulfate sodium (DSS)-induced colitis by administration of 3% DSS. Mice were treated with p-Coumaric acid derivatives (0.3, 1, or 3 mg/kg, p.o.), and disease activity index and colon length were evaluated as clinical parameters. Behavioral assessments included the open field test, novel object recognition test, elevated plus maze, and tail suspension test. Oxidative stress and inflammatory markers were quantified in colon, serum, cortex, and hippocampus, alongside histological analysis of colonic tissue. DSS administration induced clinical and histopathological alterations, increased oxidative stress, and impaired recognition memory, as well as anxiety- and depressive-like behaviors. p-Coumaric acid derivatives attenuated colonic damage, preserved tissue architecture, improved recognition memory, and reduced anxiety- and depressive-like behaviors, particularly at higher doses. These effects were associated with modulation of antioxidant defenses and reduction of lipid peroxidation and inflammatory markers. p-Coumaric acid derivatives exert protective effects in DSS-induced colitis, highlighting their potential as therapeutic agents for intestinal and neurobehavioral alterations associated with IBD.

Indexed as

ColitisCoumaric AcidsNeuroinflammatory DiseasesPropionatesAnimalsAntioxidantsBehavior, AnimalColonDextran SulfateDisease Models, AnimalLipid PeroxidationMaleMiceOxidative StressAntioxidantsCoumaric AcidsDextran Sulfatep-coumaric acidPropionatesBrazilian green propolisinflammatory bowel diseaseneuroinflammation

Identifiers

PMID42450196
PMCPMC13362371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.